Neuralstem Receives FDA Approval To Commence Spinal Cord Injury Trial

Neuralstem, Inc. announced that it received approval from the United States Food and Drug Administration to commence a Phase I safety trial of its lead cell therapy candidate, NSI-566, in chronic spinal cord injury patients.

http://www.freshnews.com/news/747336/neuralstem-receives-fda-approval-to-commence-spinal-cord-injury-trial